Exploring the Latest Research and Opportunities in T-reg Therapy
Published on 14 May 2019
T-reg Presentation
Worldwide, researchers and industry leaders are improving health outcomes for patients by utilizing the multi-functional efficacy of regulatory t cells to develop novel therapies and disease treatments. Regulatory T cells, commonly referred to as ‘T-regs’, play a critical role in maintaining order in the human immune system by regulating and suppressing excessive inflammation. Given the therapeutic potential of T-regs for patients with autoimmune diseases, cancer, and organ transplants, both researchers and industry leaders are developing novel therapies that utilize the multi-functional efficacy of T-reg cells in disease treatments to improve health outcomes for patients.
Dr. Qizhi Tang, Professor and Director at the Transplantation Research Lab in the Department of Surgery at the University of California, San Francisco, a scientific leader in T-reg function and clinical application; and Dr. Randall Alfano, Vice President at InVitria, discuss the latest developments in T-reg research and clinical application in these presentations.
Exploring the Latest Research and Manufacturing Challenges in T-reg Therapy
In the first presentation, Dr. Qizhi Tang, Professor and Director at the Transplantation Research Lab in the Department of Surgery at the University of California, San Francisco a scientific leader in T-reg function discusses the latest developments in T-reg research and clinical application. In her presentation, she shares the latest research conducted by her lab using T-reg cells for therapy, and the benefits of these therapies. Dr Tang also explores the technical challenge of commercializing T-reg therapies that require novel approaches in manufacturing and regulatory review.
View Presentation >>
Ensuring T-reg Cell Therapy Success with Blood Free and Chemically Defined Media
InVitria designs and produces the most reliable blood-free and chemically-defined products for use in cell culture, regenerative medicine, CAR-T, gene therapy, cell-based vaccines and tissue preservation. Our blood-free cell culture media is used by researchers and industry leaders on a global basis as they improve health outcomes for patients. InVitria’s scientists are designing novel cell culture media products to improve manufacturing of commercial scale regulatory T-cells for clinical use.
InVitria products not only provide improved patient safety in comparison to serum, but our custom media formulations give the leaders developing these T-reg therapies more control over their manufacturing system and supply chain, streamlining the regulatory approval process. In his presentation, Dr. Randall Alfano discusses T-reg expansion in InVitria’s chemically defined media without the use of serum or blood-derived components and why this is critical for the overall success of T-reg therapies.